In the last trading session, 1.16 million shares of the Chromadex Corp (NASDAQ:CDXC) were traded, and its beta was 1.99. Most recently the company’s share price was $7.52, and it changed around $0.25 or 3.44% from the last close, which brings the market valuation of the company to $574.41M. CDXC currently trades at a discount to its 52-week high of $7.58, offering almost -0.8% off that amount. The share price’s 52-week low was $1.32, which indicates that the current value has risen by an impressive 82.45% since then. We note from Chromadex Corp’s average daily trading volume that its 10-day average is 1.4 million shares, with the 3-month average coming to 1.08 million.
Chromadex Corp stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended CDXC as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Chromadex Corp is expected to report earnings per share of 0.02 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Chromadex Corp (NASDAQ:CDXC) trade information
Instantly CDXC has showed a green trend with a performance of 3.44% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 7.67 on recent trading dayincreased the stock’s daily price by 1.96%. The company’s shares are currently up 425.87% year-to-date, but still up 3.72% over the last five days. On the other hand, Chromadex Corp (NASDAQ:CDXC) is 117.34% up in the 30-day period. We can see from the shorts that 2.6 million shares have been sold at a short interest cover period of 9.98 day(s).
Chromadex Corp (CDXC) estimates and forecasts
Chromadex Corp share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 137.97 percent over the past six months and at a 157.14% annual growth rate that is well above the industry average of 17.80%. The year-over-year growth rate is expected to be 16.00%, up from the previous year.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 26.52M in revenue for the current quarter. 4 analysts expect Chromadex Corp to make 27.74M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 21.2M and 22.15M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 25.09%. Forecasts for the next quarter put sales growth at 25.23%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 35.83%.
CDXC Dividends
Chromadex Corp’s next quarterly earnings report is expected to be released in December.
Chromadex Corp (NASDAQ:CDXC)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 35.39% of Chromadex Corp shares, and 23.87% of them are in the hands of institutional investors. The stock currently has a share float of 36.94%. Chromadex Corp stock is held by 126.0 institutions, with VANGUARD GROUP INC being the largest institutional investor. By 2024-06-30, it held 4.5014% of the shares, which is about 3.39 million shares worth $9.24 million.
BLACKROCK INC., with 4.1422% or 3.12 million shares worth $8.51 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
